Mezzion Pharmaceuticals, Inc., a late-stage rare disease biopharmaceutical company focused on therapies for patients with single ventricle congenital heart disease and Fontan circulation, today ...

The lifesaving surgery used to treat children with single ventricle heart disease, the Fontan procedure, can pose serious health complications throughout life. The American Heart Association, devoted ...

Pediatric heart specialists in the Single Ventricle Care Program provide expert consultation and treatment of the unique issues that arise after the Norwood, Glenn and Fontan operations. For example, ...

SEOUL, South Korea, July 31, 2025 /PRNewswire/ -- Mezzion Pharmaceuticals, Inc. (Mezzion) announced that its confirmatory Phase 3 FUEL-2 study evaluating JURVIGO® (udenafil) 1 in adolescents and young ...

Sometimes a baby is born with certain types of congenital heart problems. In these cases, a type of open heart surgery called the Fontan procedure is done as the final part of a series of surgeries ...

The Fontan palliation was introduced in 1968 to treat cardiac malformations unsuitable for biventricular repair. This procedure has transformed the surgical management of congenital heart disease. In ...

Institutional financing supports continued execution of late-stage program evaluating JURVIGO® (udenafil) in patients living with Fontan circulation FORT LEE, N.J.